search
Back to results

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Primary Purpose

Hypertension

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ramipril
placebo
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension/*etiology, Blood Pressure, Pediatric, Adolescent, Child

Eligibility Criteria

6 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
  2. The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
  3. The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
  4. Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
  5. Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria:

  1. Bilateral renal artery stenosis.
  2. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
  3. Severe hypertension.
  4. Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
  5. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
  6. A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
  7. Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
  8. History of pancreatitis (active or inactive).
  9. Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.

Sites / Locations

  • UAMS College of Medicine/ Arkansas Children's Hospital
  • Woodland International Research Group, LLC
  • Impact Clinical Research
  • Neufeld Medical Group
  • Almon Clinical Research, Inc.
  • Pediatrics in Brevard
  • Watson Clinic Center for Research, Inc.
  • Emory University
  • Medical College of Georgia
  • Hawaii Pacific Health
  • Nephrology and Hypertension Consultants
  • Tinley Park Pediatric Associates
  • Kosair Children's Hospital
  • Louisiana State University
  • Craig Spiegel, MD
  • Impact Clinical Trials
  • Children's Heart Center
  • Premier Clinical Research Group
  • SUNY Upstate Syracuse, Department of Pediatrics
  • Hartrich Aquino & Hrab, PC
  • Western Wake Pediatrics
  • University of North Carolina
  • Duke Pediatric Clinical Research Program
  • North Carolina Children's and Adults Clinical Research Foundation
  • Cincinnati Children's Hospital Medical Center
  • Center for Clinical and Translational Research
  • Central Sooner Research
  • The University of Oklahoma
  • Oregon Health and Science University
  • Northwest Pediatric Kidney Specialists, LLC
  • Thomas Jefferson University Hospital
  • Holston Medical Group
  • Le Bonheur Children's Hospital
  • South East Texas Cardiology Associates
  • University of Texas Medical Center
  • University of Utah
  • University of Virginia
  • Huguenot Pediatrics
  • Children's Specialty Group
  • Hospital de Niños "Dr. Ricardo Gutiérrez"
  • Hospital General Interzonal "Dr. José Penna"
  • Hospital Interzonal Especializado Materno Infantil
  • Hospital Italiano de Buenos Aires
  • Hospital de Niños Juan Carlos Navarro
  • Centro Infantil del Rínon
  • Clínica Las Condes
  • Hospital de Niños Roberto del Rio
  • Hospital Luis Calvo Mackena
  • Hospital Dr. Gustavo Fricke
  • Fundación Bios
  • Fundación Cardio Infantil - Instituto de Cardiología
  • Hospital de San Jose
  • Instituto Nacional del Riñón
  • Hospital Pablo Tobon Uribe
  • Hospital Universitario San Vicente de Paul
  • Hospital Pablo Tobon Uribe
  • Gujarat Kidney Foundation, Jivraj Mehta Hospital
  • Heart Care Clinic
  • St. John's Hospital
  • Institute of Child Health & Hospital for Children
  • AIl India Institute medical sciences
  • Apollo Hospital
  • Maulana Azad Medical College and Lok Nayak Hospital
  • Apollo Hospital Hyderabad
  • Nizam's Institute of Medical Sciences
  • Christian Medical College and Hospital
  • Jaslok Hospital and Research Centre
  • KEM Hospital Research Centre
  • Kerala Institute of Medical Science
  • Klinika Nefrologii Dzieciecej SPSK nr 1 ACK AMG
  • Katedra i Klinika Kardiologii Dzieciecej SK nr 6, Gornoslaskie Centrum Zdrowia Dziecka i Matki, Slaska AM
  • II Katedra Pediatrii, Klinika Kardiologii Dzieciecej UM w Lodzi
  • Klinika Nefrologii i Dializoterapii, Instytut Centrum Zdrowia Matki Polki
  • Klinika Kardiologii i Nefrologii Dzieciecej AM
  • I Klinika Chorob Dzieci SPSK nr 1 PAM
  • Oddzial Nefrologi Dzieciecej ze Stacja Dializ SSP ZOZ nad Dziecklem i Mlodzieza
  • Oddzial Pediatrii i Nefrologii ze Stacja Dializ, Wojewodzki Szpital Dzieciecy
  • Klinika Nefrologii i Transplantacji Nerek, Instytut Pomnik Centrum Zdrowia Dziecka
  • Klinika Nefrologii Pediatrycznej AM
  • Benmed Park Clinic
  • Chris Hani Baragwanath
  • Global Clinical Trial Centre
  • Potchefstroom Medi-Clinic
  • Eastmed Medical centre
  • Jubilee CTC Jubilee Hospital
  • Pretoria Academic Hospital
  • Zuid Afrikaans Hospital
  • Sandton Clinical Research Centre
  • Istanbul University Istanbul Medical Faculty Pediatric Nephrology
  • Marmara University Medical Faculty Pediatric Nephrology
  • Dokuzeylul University Medical Faculty Pediatric Nephrology
  • Ondokummayis University Medical Faculty Pediatric Nephrology
  • Dnepropetrovsk Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital
  • Kharkov State University,Dept. of hospital pediatric on the bases of Regional Children's Hospital
  • NMU n.b. Bogomolets, on b.o. Chil. Clin.Hosp.#2, Department of Pediatrics #2
  • Institute of Pediatrics and Obstetrics AMS of Ukraine, Department of ecology related health problems
  • Danylo Halytskiy Lviv NationalMedical University, Department of Faculty
  • Odessa State Medical University, Dept. of hospital pediatric and neonotology on the bases of Regional Children Hospital
  • Crim.St. Med. Uni. On b.o. Rep. Child.Clin.Hosp. Chair of Pediat. W.c. of Physioth. Of the Postgr.dept
  • Uzhorod National University, Medical faculty, Department of Children's disease with course of Infection disease on the basis of City Children's Clinical Hospital.
  • Vinnitsa National Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Placebo

ramipril low dose

ramipril mid dose

ramipril high dose

Arm Description

once per day

0.3125, 0.625, or 1.25 mg once a day, based on subject weight

1.25, 2.5, or 5 mg once a day, based on subject weight

5, 10, or 20 mg once a day, based on subject weight

Outcomes

Primary Outcome Measures

Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo

Secondary Outcome Measures

Change From Baseline to 4 Weeks in Trough Sitting Diastolic Blood Pressure
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Change From Baseline to 4 Weeks in Serum Creatinine
Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Serum Potassium
Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Schwartz Formula Glomerular Filtration Rate (GFR)
Value at end of treatment (up to 4 weeks) minus value at baseline; GFR is a measure of kidney function.

Full Information

First Posted
October 17, 2006
Last Updated
June 6, 2012
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00389519
Brief Title
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Terminated
Why Stopped
A planned interim analysis was performed after approx. 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.
Study Start Date
October 2006 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Pfizer

4. Oversight

5. Study Description

Brief Summary
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
Detailed Description
Information is needed on the treatment of hypertension in children and adolescents with antihypertensive drugs like ramipril. The study will assess the safety and blood pressure effects of several doses of the antihypertensive drug ramipril in children and adolescents age 6-16 years. Approximately 450 children will be given placebo, or 1 of the 3 doses of ramipril. The treatment assigned will be done by chance, like flipping a coin. Approximately 120 study centers throughout the world will participate in the trial. Each child will complete a 1- to 4-week Screening Period where they will stop taking their current blood pressure lowering drug(s), a 4-week Treatment Period where they will receive placebo or one of the ramipril doses, and a Follow-up visit 1 week after completion of the Treatment Period. Children diagnosed with hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (U.S. report), will be included in the study if their blood pressure meets certain values. Each child will complete a minimum of 6 and up to 9 clinic visits over the course of the study during which procedures and assessments of blood pressure and safety will be performed. In addition, a child's parents/guardians will be instructed to measure their child's blood pressure at home between clinic visits. A planned interim analysis was performed after approximately 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension/*etiology, Blood Pressure, Pediatric, Adolescent, Child

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
422 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
once per day
Arm Title
ramipril low dose
Arm Type
Experimental
Arm Description
0.3125, 0.625, or 1.25 mg once a day, based on subject weight
Arm Title
ramipril mid dose
Arm Type
Experimental
Arm Description
1.25, 2.5, or 5 mg once a day, based on subject weight
Arm Title
ramipril high dose
Arm Type
Experimental
Arm Description
5, 10, or 20 mg once a day, based on subject weight
Intervention Type
Drug
Intervention Name(s)
ramipril
Other Intervention Name(s)
Altace
Intervention Description
once a day oral ramipril capsules given for 4 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
once a day oral placebo capsule for 4 weeks
Primary Outcome Measure Information:
Title
Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure
Description
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Time Frame
Baseline to 4 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline to 4 Weeks in Trough Sitting Diastolic Blood Pressure
Description
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Time Frame
Baseline to 4 weeks
Title
Change From Baseline to 4 Weeks in Serum Creatinine
Description
Value at end of treatment (up to 4 weeks) minus value at baseline
Time Frame
Baseline up to 4 weeks
Title
Change From Baseline to 4 Weeks in Serum Potassium
Description
Value at end of treatment (up to 4 weeks) minus value at baseline
Time Frame
Baseline up to 4 weeks
Title
Change From Baseline to 4 Weeks in Schwartz Formula Glomerular Filtration Rate (GFR)
Description
Value at end of treatment (up to 4 weeks) minus value at baseline; GFR is a measure of kidney function.
Time Frame
Baseline up to 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height. The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator. The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg. Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception. Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed. Exclusion Criteria: Bilateral renal artery stenosis. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg. Severe hypertension. Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine. A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure. Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L. History of pancreatitis (active or inactive). Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.
Facility Information:
Facility Name
UAMS College of Medicine/ Arkansas Children's Hospital
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72202
Country
United States
Facility Name
Woodland International Research Group, LLC
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
Facility Name
Impact Clinical Research
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Neufeld Medical Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Almon Clinical Research, Inc.
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Pediatrics in Brevard
City
Cocoa Beach
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
Watson Clinic Center for Research, Inc.
City
Lakeland
State/Province
Florida
ZIP/Postal Code
33805
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Medical College of Georgia
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Facility Name
Hawaii Pacific Health
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96813
Country
United States
Facility Name
Nephrology and Hypertension Consultants
City
Park Ridge
State/Province
Illinois
ZIP/Postal Code
60068
Country
United States
Facility Name
Tinley Park Pediatric Associates
City
Tinley Park
State/Province
Illinois
ZIP/Postal Code
60477
Country
United States
Facility Name
Kosair Children's Hospital
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Louisiana State University
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Facility Name
Craig Spiegel, MD
City
Bridgeton
State/Province
Missouri
ZIP/Postal Code
63044
Country
United States
Facility Name
Impact Clinical Trials
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Children's Heart Center
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89109
Country
United States
Facility Name
Premier Clinical Research Group
City
Toms River
State/Province
New Jersey
ZIP/Postal Code
08755
Country
United States
Facility Name
SUNY Upstate Syracuse, Department of Pediatrics
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
Hartrich Aquino & Hrab, PC
City
Williamsville
State/Province
New York
ZIP/Postal Code
14221
Country
United States
Facility Name
Western Wake Pediatrics
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27518
Country
United States
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27514
Country
United States
Facility Name
Duke Pediatric Clinical Research Program
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
North Carolina Children's and Adults Clinical Research Foundation
City
Sylva
State/Province
North Carolina
ZIP/Postal Code
28779
Country
United States
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
Center for Clinical and Translational Research
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Facility Name
Central Sooner Research
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Facility Name
The University of Oklahoma
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74135
Country
United States
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97201
Country
United States
Facility Name
Northwest Pediatric Kidney Specialists, LLC
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States
Facility Name
Thomas Jefferson University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Holston Medical Group
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Le Bonheur Children's Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
South East Texas Cardiology Associates
City
Beaumont
State/Province
Texas
ZIP/Postal Code
77701
Country
United States
Facility Name
University of Texas Medical Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84108
Country
United States
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
Huguenot Pediatrics
City
Midlothian
State/Province
Virginia
ZIP/Postal Code
23113
Country
United States
Facility Name
Children's Specialty Group
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
Hospital de Niños "Dr. Ricardo Gutiérrez"
City
Buenos Aires
Country
Argentina
Facility Name
Hospital General Interzonal "Dr. José Penna"
City
Buenos Aires
Country
Argentina
Facility Name
Hospital Interzonal Especializado Materno Infantil
City
Buenos Aires
Country
Argentina
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
Country
Argentina
Facility Name
Hospital de Niños Juan Carlos Navarro
City
San Juan
Country
Argentina
Facility Name
Centro Infantil del Rínon
City
Tucomán
Country
Argentina
Facility Name
Clínica Las Condes
City
Santiago
Country
Chile
Facility Name
Hospital de Niños Roberto del Rio
City
Santiago
Country
Chile
Facility Name
Hospital Luis Calvo Mackena
City
Santiago
Country
Chile
Facility Name
Hospital Dr. Gustavo Fricke
City
Vina del Mar
Country
Chile
Facility Name
Fundación Bios
City
Barranquilla
Country
Colombia
Facility Name
Fundación Cardio Infantil - Instituto de Cardiología
City
Bogotá
Country
Colombia
Facility Name
Hospital de San Jose
City
Bogotá
Country
Colombia
Facility Name
Instituto Nacional del Riñón
City
Bogotá
Country
Colombia
Facility Name
Hospital Pablo Tobon Uribe
City
Medellin
Country
Colombia
Facility Name
Hospital Universitario San Vicente de Paul
City
Medellin
Country
Colombia
Facility Name
Hospital Pablo Tobon Uribe
City
Medellín
Country
Colombia
Facility Name
Gujarat Kidney Foundation, Jivraj Mehta Hospital
City
Ahmedabad
Country
India
Facility Name
Heart Care Clinic
City
Ahmedabad
Country
India
Facility Name
St. John's Hospital
City
Bangalore
Country
India
Facility Name
Institute of Child Health & Hospital for Children
City
Chennai
Country
India
Facility Name
AIl India Institute medical sciences
City
Delhi
Country
India
Facility Name
Apollo Hospital
City
Delhi
Country
India
Facility Name
Maulana Azad Medical College and Lok Nayak Hospital
City
Delhi
Country
India
Facility Name
Apollo Hospital Hyderabad
City
Hyderabaad
Country
India
Facility Name
Nizam's Institute of Medical Sciences
City
Hyderabaad
Country
India
Facility Name
Christian Medical College and Hospital
City
Ludhiana
Country
India
Facility Name
Jaslok Hospital and Research Centre
City
Mumbai
Country
India
Facility Name
KEM Hospital Research Centre
City
Pune
Country
India
Facility Name
Kerala Institute of Medical Science
City
Trivandrum
Country
India
Facility Name
Klinika Nefrologii Dzieciecej SPSK nr 1 ACK AMG
City
Gdansk
Country
Poland
Facility Name
Katedra i Klinika Kardiologii Dzieciecej SK nr 6, Gornoslaskie Centrum Zdrowia Dziecka i Matki, Slaska AM
City
Katowice
Country
Poland
Facility Name
II Katedra Pediatrii, Klinika Kardiologii Dzieciecej UM w Lodzi
City
Lodz
Country
Poland
Facility Name
Klinika Nefrologii i Dializoterapii, Instytut Centrum Zdrowia Matki Polki
City
Lodz
Country
Poland
Facility Name
Klinika Kardiologii i Nefrologii Dzieciecej AM
City
Poznan
Country
Poland
Facility Name
I Klinika Chorob Dzieci SPSK nr 1 PAM
City
Szczecin
Country
Poland
Facility Name
Oddzial Nefrologi Dzieciecej ze Stacja Dializ SSP ZOZ nad Dziecklem i Mlodzieza
City
Szczecin
Country
Poland
Facility Name
Oddzial Pediatrii i Nefrologii ze Stacja Dializ, Wojewodzki Szpital Dzieciecy
City
Torun
Country
Poland
Facility Name
Klinika Nefrologii i Transplantacji Nerek, Instytut Pomnik Centrum Zdrowia Dziecka
City
Warszawa
Country
Poland
Facility Name
Klinika Nefrologii Pediatrycznej AM
City
Wroclaw
Country
Poland
Facility Name
Benmed Park Clinic
City
Benoni
Country
South Africa
Facility Name
Chris Hani Baragwanath
City
Johannesburg
Country
South Africa
Facility Name
Global Clinical Trial Centre
City
Port Elizabeth
Country
South Africa
Facility Name
Potchefstroom Medi-Clinic
City
Potchefstroom
Country
South Africa
Facility Name
Eastmed Medical centre
City
Pretoria
Country
South Africa
Facility Name
Jubilee CTC Jubilee Hospital
City
Pretoria
Country
South Africa
Facility Name
Pretoria Academic Hospital
City
Pretoria
Country
South Africa
Facility Name
Zuid Afrikaans Hospital
City
Pretoria
Country
South Africa
Facility Name
Sandton Clinical Research Centre
City
Sandton
Country
South Africa
Facility Name
Istanbul University Istanbul Medical Faculty Pediatric Nephrology
City
Istanbul
Country
Turkey
Facility Name
Marmara University Medical Faculty Pediatric Nephrology
City
Istanbul
Country
Turkey
Facility Name
Dokuzeylul University Medical Faculty Pediatric Nephrology
City
Izmir
Country
Turkey
Facility Name
Ondokummayis University Medical Faculty Pediatric Nephrology
City
Samsun
Country
Turkey
Facility Name
Dnepropetrovsk Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital
City
Dnepropetrovsk
Country
Ukraine
Facility Name
Kharkov State University,Dept. of hospital pediatric on the bases of Regional Children's Hospital
City
Kharkov
Country
Ukraine
Facility Name
NMU n.b. Bogomolets, on b.o. Chil. Clin.Hosp.#2, Department of Pediatrics #2
City
Kiev
Country
Ukraine
Facility Name
Institute of Pediatrics and Obstetrics AMS of Ukraine, Department of ecology related health problems
City
Kyiv
Country
Ukraine
Facility Name
Danylo Halytskiy Lviv NationalMedical University, Department of Faculty
City
Lviv
Country
Ukraine
Facility Name
Odessa State Medical University, Dept. of hospital pediatric and neonotology on the bases of Regional Children Hospital
City
Odessa
Country
Ukraine
Facility Name
Crim.St. Med. Uni. On b.o. Rep. Child.Clin.Hosp. Chair of Pediat. W.c. of Physioth. Of the Postgr.dept
City
Simferopol
Country
Ukraine
Facility Name
Uzhorod National University, Medical faculty, Department of Children's disease with course of Infection disease on the basis of City Children's Clinical Hospital.
City
Uzhorod
Country
Ukraine
Facility Name
Vinnitsa National Medical Academy, Department of Hospital Pediatrics on the bases of Regional Pediatric Hospital
City
Vinnitsa
Country
Ukraine

12. IPD Sharing Statement

Learn more about this trial

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

We'll reach out to this number within 24 hrs